- Home
- MNTK vs PBYI Comparison
MNTK vs PBYI Comparison
Compare MNTK & PBYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MNTK | PBYI |
|---|---|---|
| Founded | 1980 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Natural Gas Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 257.5M | 263.4M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | MNTK | PBYI |
|---|---|---|
| Price | $1.74 | $6.88 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | $3.33 | ★ $7.00 |
| AVG Volume (30 Days) | ★ 798.1K | 436.4K |
| Earning Date | 03-11-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 59.87 |
| EPS | N/A | ★ 0.74 |
| Revenue | $160,682,000.00 | ★ $211,995,000.00 |
| Revenue This Year | $2.45 | N/A |
| Revenue Next Year | $15.31 | N/A |
| P/E Ratio | ★ N/A | $9.32 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.37 | $2.58 |
| 52 Week High | $4.71 | $7.29 |
Technical Indicators
Market Signals| Indicator | MNTK | PBYI |
|---|---|---|
| Relative Strength Index (RSI) | 54.60 | 59.70 |
| Support Level | $1.62 | $6.75 |
| Resistance Level | $1.94 | $7.29 |
| Average True Range (ATR) | 0.20 | 0.35 |
| MACD | 0.04 | 0.01 |
| Stochastic Oscillator | 48.61 | 59.02 |
Price Performance
Historical ComparisonAbout MNTK Montauk Renewables Inc.
Montauk Renewables Inc is a renewable energy company. It specializes in the recovery and processing of biogas from landfills and other non-fossil fuel sources for beneficial use as a replacement for fossil fuels. The firm develops, owns, and operates RNG projects that supply renewable fuel into the transportation and electrical power sectors. Montauk operates in two segments namely Renewable Natural Gas and Renewable Electricity Generation. It generates a majority of its revenue from the Renewable Natural Gas segment.
About PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis resulting into apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.